Who are Icosapent (MND-2119)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eicosapentaenoic acid ethyl ester, Ethyl-EPA (Miraxion™).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/icosapent-mnd-2119.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Icosapent (MND-2119) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Icosapent (MND-2119) (Icosapent (MND-2119)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Omega-3 fatty acid / Triglyceride-lowering agent. Area: Cardiovascular.

phase 3 Omega-3 fatty acid / Triglyceride-lowering agent Multiple lipid metabolism pathways; FFAR1 (GPR40), FFAR4 (GPR120) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Icosapent (MND-2119) (Icosapent (MND-2119)) — Mochida Pharmaceutical Company, Ltd.. Icosapent is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA) that reduces triglycerides and modulates lipid metabolism.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Icosapent (MND-2119) TARGET	Icosapent (MND-2119)	Mochida Pharmaceutical Company, Ltd.	phase 3	Omega-3 fatty acid / Triglyceride-lowering agent	Multiple lipid metabolism pathways; FFAR1 (GPR40), FFAR4 (GPR120)
Eicosapentaenoic acid ethyl ester	Eicosapentaenoic acid ethyl ester	Yamaguchi University Hospital	marketed	Omega-3 fatty acid / Triglyceride-lowering agent
Ethyl-EPA (Miraxion™)	Ethyl-EPA (Miraxion™)	Amarin Neuroscience Ltd	phase 3	Omega-3 fatty acid / Triglyceride-lowering agent

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Omega-3 fatty acid / Triglyceride-lowering agent class)

Amarin Neuroscience Ltd · 1 drug in this class
Mochida Pharmaceutical Company, Ltd. · 1 drug in this class
Yamaguchi University Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Icosapent (MND-2119) — Competitive Intelligence Brief. https://druglandscape.com/ci/icosapent-mnd-2119. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab